Progress of bendamustine in treatment of multiple myeloma

VernacularTitle:苯达莫司汀治疗多发性骨髓瘤研究进展
Author: Guihua ZHU ¹ ; Wanchuan ZHUANG
Author Information

1. 连云港市第二人民医院血液内科，连云港　222000
Keywords: Multiple myeloma; Antineoplastic combined chemotherapy protocols; Bendamustine
From: Journal of Leukemia & Lymphoma 2022;31(12):766-768
CountryChina
Language:Chinese
Abstract: Bendamustine, a bifunctional derivate of nitrogen mustard, is an attractive treatment option for multiple myeloma (MM) due to its specific mode of activity, favorable toxicity profile, and clinical activity in patients resistant to alkylating agent. Bendamustine single agent and its combination with immunomodulators or proteasome inhibitors have been widely used in the relapsed/refractory MM patients. Bendamustine has brought the longer progression-free survival, overall survival time and deeper remission in the autologous stem cell transplantation pre-conditioning for MM patients. This paper reviews the treatment progress of bendamustine for MM.